Ziftomenib Shows Clinically Meaningful Activity in Heavily Pretreated NPM1‑Mutated AML — A Targeted Option for a Molecularly Defined Relapse Population
Posted inHematology-Oncology news

Ziftomenib Shows Clinically Meaningful Activity in Heavily Pretreated NPM1‑Mutated AML — A Targeted Option for a Molecularly Defined Relapse Population

In the phase II registration cohort of KOMET‑001, oral menin inhibitor ziftomenib achieved a CR/CRh rate of 22% (61% MRD negativity) and an ORR of 33% in relapsed/refractory NPM1‑mutated AML with manageable toxicity, supporting further study and potential use as a molecularly targeted salvage option.
ICU Structure and Care Processes Explain Much of VAP and CLABSI Variation in Brazilian ICUs: Findings from a 50‑Unit IMPACTO‑MR Nested Cohort
Posted inCritical Care Infectious Diseases news

ICU Structure and Care Processes Explain Much of VAP and CLABSI Variation in Brazilian ICUs: Findings from a 50‑Unit IMPACTO‑MR Nested Cohort

A 50‑ICU nested cohort from the IMPACTO‑MR platform links ICU-level structure and care processes to substantially different ventilator‑associated pneumonia and central line‑associated bloodstream infection rates, highlighting modifiable institutional targets in LMIC intensive care.
School Feeding Programs: Comprehensive Evidence on Benefits for Socioeconomically Disadvantaged School Children’s Physical and Psychological Health
Posted inClinical Updates news Pediatrics Psychiatry Public Health

School Feeding Programs: Comprehensive Evidence on Benefits for Socioeconomically Disadvantaged School Children’s Physical and Psychological Health

This review synthesizes global evidence, including meta-analyses, showing that school feeding programs modestly improve math achievement, enrollment, and growth metrics in socioeconomically disadvantaged children, with limited effects on reading or attendance, and uncertain impact on overweight/obesity.
No Net Benefit from Adding Antiplatelet Therapy to Anticoagulation After Stroke in Patients with Atrial Fibrillation and Atherosclerosis: Results from the ATIS‑NVAF Randomized Trial
Posted inCardiology Neurology news

No Net Benefit from Adding Antiplatelet Therapy to Anticoagulation After Stroke in Patients with Atrial Fibrillation and Atherosclerosis: Results from the ATIS‑NVAF Randomized Trial

In older patients with ischemic stroke/TIA, nonvalvular atrial fibrillation, and atherosclerotic cardiovascular disease, adding a single antiplatelet agent to anticoagulation did not reduce ischemic events but markedly increased bleeding, providing no net clinical benefit versus anticoagulant monotherapy.
Digital twins suggest APRV can lower mechanical power and tidal recruitment versus PCV in ARDS — modeling evidence and clinical implications
Posted inCritical Care news Respiratory

Digital twins suggest APRV can lower mechanical power and tidal recruitment versus PCV in ARDS — modeling evidence and clinical implications

High-fidelity digital twins of 98 ARDS patients indicate APRV (Phigh 25/Plow 0, long Tinsp, short Tlow to 75% peak expiratory flow) reduced mechanical power by ~32% and tidal recruitment by ~34% versus recorded PCV, at the cost of controlled hypercapnia; clinical trials are needed.
Pregnancy DMT Management in Multiple Sclerosis Increases Relapse Risk — Anti‑CD20 Before Conception Is Most Protective
Posted inNeurology news Rheumatology

Pregnancy DMT Management in Multiple Sclerosis Increases Relapse Risk — Anti‑CD20 Before Conception Is Most Protective

A large French registry study shows that how disease-modifying therapies (DMTs) are managed during pregnancy meaningfully affects relapse rates in relapsing‑onset MS; prolonged natalizumab interruption and fingolimod use carry the highest risks, while preconception anti‑CD20 strategies are most protective.
RBC Transfusions in Early Sepsis Resuscitation: Common, Complex, and Potentially Harmful Above a 10 g/dL Threshold
Posted inAnesthesiology Critical Care Hematology-Oncology news

RBC Transfusions in Early Sepsis Resuscitation: Common, Complex, and Potentially Harmful Above a 10 g/dL Threshold

In a multicenter Korean sepsis cohort, early RBC transfusions were frequent and driven by illness severity. No overall 60‑day mortality difference was seen after propensity matching, but transfusion was associated with harm at hemoglobin ≥10 g/dL and a possible benefit below that threshold.
急性虚血性脳卒中における補助的静注アルガトロバンまたはエプチフィバチド投与：MOST無作為化臨床試験によるエビデンス
Posted inClinical Updates Neurology news

急性虚血性脳卒中における補助的静注アルガトロバンまたはエプチフィバチド投与：MOST無作為化臨床試験によるエビデンス

Recent multi-site randomized evidence demonstrates that adding intravenous argatroban or eptifibatide to standard thrombolysis within 3 hours of stroke onset does not improve functional recovery and is associated with increased mortality, including in patients undergoing mechanical thrombectomy.